[{"address1": "500 North Beacon Street", "address2": "4th Floor", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "857 285 5300", "website": "https://www.kymeratx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 218, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bruce L. Booth DPHIL, Ph.D.", "age": 50, "title": "Co-Founder & Independent Chairman", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 70000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nello  Mainolfi M.D., Ph.D.", "age": 45, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 1226500, "exercisedValue": 1110312, "unexercisedValue": 37845672}, {"maxAge": 1, "name": "Mr. Bruce N. Jacobs CFA", "title": "Chief Financial Officer", "fiscalYear": 2024, "totalPay": 754540, "exercisedValue": 703665, "unexercisedValue": 9900757}, {"maxAge": 1, "name": "Dr. Jeremy G. Chadwick Ph.D.", "age": 61, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 719400, "exercisedValue": 0, "unexercisedValue": 838368}, {"maxAge": 1, "name": "Ms. Ellen V. Chiniara Esq., J.D.", "age": 65, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 696080, "exercisedValue": 0, "unexercisedValue": 1659227}, {"maxAge": 1, "name": "Dr. Jared A. Gollob M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 768400, "exercisedValue": 3280617, "unexercisedValue": 6586792}, {"maxAge": 1, "name": "Ms. Justine E. Koenigsberg", "title": "Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  Weisbach", "title": "Head of People & Culture", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juliet  Williams B.A Ph.D.", "title": "Head of Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Noah  Goodman M.B.A.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 42.2, "open": 42.88, "dayLow": 42.73, "dayHigh": 44.0, "regularMarketPreviousClose": 42.2, "regularMarketOpen": 42.88, "regularMarketDayLow": 42.73, "regularMarketDayHigh": 44.0, "payoutRatio": 0.0, "beta": 2.177, "forwardPE": -13.990354, "volume": 551530, "regularMarketVolume": 551530, "averageVolume": 716535, "averageVolume10days": 657980, "averageDailyVolume10Day": 657980, "bid": 31.1, "ask": 54.88, "bidSize": 2, "askSize": 2, "marketCap": 3110860544, "fiftyTwoWeekLow": 19.445, "fiftyTwoWeekHigh": 53.27, "priceToSalesTrailing12Months": 69.57707, "fiftyDayAverage": 43.4516, "twoHundredDayAverage": 38.52265, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2531129344, "profitMargins": 0.0, "floatShares": 46960337, "sharesOutstanding": 71497600, "sharesShort": 7611533, "sharesShortPriorMonth": 7572642, "sharesShortPreviousMonthDate": 1752537600, "dateShortInterest": 1755216000, "sharesPercentSharesOut": 0.1065, "heldPercentInsiders": 0.024519999, "heldPercentInstitutions": 1.0999299, "shortRatio": 11.93, "shortPercentOfFloat": 0.1314, "impliedSharesOutstanding": 73378200, "bookValue": 13.769, "priceToBook": 3.159997, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -275433984, "trailingEps": -3.49, "forwardEps": -3.11, "enterpriseToRevenue": 56.611, "enterpriseToEbitda": -8.297, "52WeekChange": -0.05903977, "SandP52WeekChange": 0.18469036, "quoteType": "EQUITY", "currentPrice": 43.51, "targetHighPrice": 70.0, "targetLowPrice": 53.0, "targetMeanPrice": 60.36842, "targetMedianPrice": 60.0, "recommendationKey": "none", "numberOfAnalystOpinions": 19, "totalCash": 665444992, "totalCashPerShare": 9.307, "ebitda": -305056000, "totalDebt": 85714000, "quickRatio": 8.059, "currentRatio": 8.32, "totalRevenue": 44711000, "debtToEquity": 8.823, "revenuePerShare": 0.564, "returnOnAssets": -0.19919, "returnOnEquity": -0.33257, "grossProfits": -246159008, "freeCashflow": -153841376, "operatingCashflow": -251008000, "revenueGrowth": -0.553, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -7.36816, "financialCurrency": "USD", "symbol": "KYMR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 3.10426, "regularMarketPrice": 43.51, "shortName": "Kymera Therapeutics, Inc.", "longName": "Kymera Therapeutics, Inc.", "exchange": "NGM", "messageBoardId": "finmb_542085131", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketTime": 1757108281, "regularMarketTime": 1757102402, "marketState": "CLOSED", "fiftyTwoWeekLowChange": 24.064999, "fiftyTwoWeekLowChangePercent": 1.2375932, "fiftyTwoWeekRange": "19.445 - 53.27", "fiftyTwoWeekHighChange": -9.760002, "fiftyTwoWeekHighChangePercent": -0.18321761, "fiftyTwoWeekChangePercent": -5.9039774, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1598016600000, "postMarketChangePercent": 0.0, "postMarketPrice": 43.51, "postMarketChange": 0.0, "regularMarketChange": 1.31, "regularMarketDayRange": "42.73 - 44.0", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 716535, "earningsTimestamp": 1754884800, "earningsTimestampStart": 1762432200, "earningsTimestampEnd": 1762432200, "earningsCallTimestampStart": 1754915400, "earningsCallTimestampEnd": 1754915400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.49, "epsForward": -3.11, "epsCurrentYear": -3.39273, "priceEpsCurrentYear": -12.82448, "fiftyDayAverageChange": 0.0583992, "fiftyDayAverageChangePercent": 0.0013440058, "twoHundredDayAverageChange": 4.9873466, "twoHundredDayAverageChangePercent": 0.1294653, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-08-21", "cryptoTradeable": false, "displayName": "Kymera Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-09-06"}]